We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It’s critical for a solution Covid-19 to stop people dying from not just respiratory failure ARDS but also organ failure so will the research that the professionals already have and which is key here with the trials with other JAK inhibitors that would be an indicator whether Sareum’s preclinical autoimmune data can show that it can be a solution, we can see from the research in the public domain that there is a good chance for this!
Fadec - Sareum would not use the word “compelling” in scientific terms unless findings are really convincing. Surely we will get a partner soon to investigate Treatment of the Covid Cytokines storms!
On the new TYK2/COVID-19 page, they have the cash and the potential grant money, and are looking too progress with a partner or license out, it would be nice to know some of the details too!
“Whilst developing SDC-1801, we have produced compelling cellular and in-vivo data in models of autoimmune disease to demonstrate the beneficial effects of SDC-1801 in modulating the key cytokines involved in the cytokine storm phase of Covid-19. Details can be made available to potential funding, collaboration and/or licensing partners on request.“
Yep. All guesswork. A possibility is interested parties have requested additional pre clinical data to de risk any investment
Basser
Exactly my thoughts.
Agree we are all guessing.
My take on this (ie a guess!) is that Tim etc have been in discussions with a number of interested parties, because it will be well known that SDC-01 is the last second generation THK/ Jak 1 available for sale and that it has demonstrated low toxicity. This alone is bound to have attracted a lot of Pharma interest. What may have happened is that offers have come in which Sareum deem to be unacceptable - they are clearly looking for a deal with a large upfront payment. These negotiations take time especially if you are dealing with a number of interested parties. And during this negotiating period they have not until now been able to raise funding to progress the molecule due to the low share price. The Covid Share spike has given them a window of opportunity to raise funds which they have taken. This puts them in a stronger negotiating position going into clinical trials. So I feel more confident that a good deal for the company and its shareholders can now be obtained. As I have said earlier this to me means an exciting time leading up to clinical times which hopefully will be around the end of the year - as per Tim’s timetable.
All just a guess.
Let’s face it, no one knows what’s happening, it’s all best guess.
If we are in negotiations, Tim can say f@@k all about it and that’s probably why he’s so nervous on camera as he can’t give anything away.
My thoughts for what they are worth is the money raised is to strengthen our negotiation position.
Big sells not big seeks.
I knew MTD hadn't been found. It wasn't that. Last years raise was to progress TYK2 to clinic. I don't mean a deal. We had the money and the time. So why aren't we there yet? Exactly what progress has been made on TYK2 since the last raise, which was For TYK2? We've had a couple of big seeks this week. Have we lost a LTH because of this?
I thought MTD would only be realised once we started Phase1 trials or made an application for commencement of. Do we not need to trial them in humans to realise what the MTD is or am I barking up the wrong tree. RMM should be able to enlighten us on this.
i was thinking the same, i thought we had put the MTD to bed a long time back, what do you think this means?, is this why we are not getting much attention do you think from a potential buyer?
If we are not ready for this as yet what are the NED's on board for, weren't they put in place after the MTD work?